I期临床-话题@MedSci

#I期临床#

570篇内容 | 7040人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652886, encodeId=4d8f165288617, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=89, createdTime=2019-05-06, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652880, encodeId=dec2165288032, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=天境生物宣布完成自主新药TJM2美国I期临床首次人体给药, objectType=article, longId=162626, objectId=1a9e16262659, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a9e16262659, replyNumber=0, likeNumber=46, createdTime=2019-06-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a9e16262659, moduleTitle=天境生物宣布完成自主新药TJM2美国I期临床首次人体给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a9e16262659)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652846, encodeId=6408165284669, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, objectType=article, longId=156414, objectId=bb9a156414cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb9a156414cc, replyNumber=0, likeNumber=0, createdTime=2019-02-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb9a156414cc, moduleTitle="PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb9a156414cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652859, encodeId=e79c1652859ef, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Biomed Res Int：牙槽嵴成形术中侧向Ramus皮质骨板同时使用颊脂垫衍生细胞和自体骨：I期临床试验, objectType=article, longId=160250, objectId=a20c16025024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a20c16025024, replyNumber=0, likeNumber=59, createdTime=2020-01-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a20c16025024, moduleTitle=Biomed Res Int：牙槽嵴成形术中侧向Ramus皮质骨板同时使用颊脂垫衍生细胞和自体骨：I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a20c16025024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652889, encodeId=6cb9165288952, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, objectType=article, longId=165652, objectId=69a116565258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a116565258, replyNumber=0, likeNumber=70, createdTime=2020-02-17, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a116565258, moduleTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a116565258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652885, encodeId=20881652885fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, objectType=article, longId=164219, objectId=e04a16421946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e04a16421946, replyNumber=0, likeNumber=77, createdTime=2020-03-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e04a16421946, moduleTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e04a16421946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652895, encodeId=e68516528951a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, objectType=article, longId=166254, objectId=0b72166254e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b72166254e3, replyNumber=0, likeNumber=52, createdTime=2020-04-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b72166254e3, moduleTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b72166254e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652926, encodeId=c5871652926b8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功, objectType=article, longId=177716, objectId=cb201e7716eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb201e7716eb, replyNumber=0, likeNumber=76, createdTime=2019-12-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb201e7716eb, moduleTitle=Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb201e7716eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652866, encodeId=378316528668e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, objectType=article, longId=160532, objectId=d280160532df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d280160532df, replyNumber=0, likeNumber=61, createdTime=2019-05-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d280160532df, moduleTitle=FDA批准新型心血管支持液VBI-1进入II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d280160532df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652907, encodeId=82c6165290e8c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=短肠综合征：双效多肽药物ZP7570正在进行I期临床试验, objectType=article, longId=174327, objectId=f0d81e432731, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0d81e432731, replyNumber=0, likeNumber=69, createdTime=2020-03-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0d81e432731, moduleTitle=短肠综合征：双效多肽药物ZP7570正在进行I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0d81e432731)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652852, encodeId=960d165285296, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=II期j临床试验成功而III期临床失败的案例教训, objectType=article, longId=157416, objectId=f2d315e41677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2d315e41677, replyNumber=0, likeNumber=48, createdTime=2019-06-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2d315e41677, moduleTitle=II期j临床试验成功而III期临床失败的案例教训, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2d315e41677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652857, encodeId=adaf165285e58, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet Oncol：张力教授领衔——中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告, objectType=article, longId=159648, objectId=e51715964873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e51715964873, replyNumber=0, likeNumber=69, createdTime=2019-04-14, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e51715964873, moduleTitle=Lancet Oncol：张力教授领衔——中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e51715964873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652901, encodeId=c4151652901c4, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, objectType=article, longId=167610, objectId=0be116e61073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be116e61073, replyNumber=0, likeNumber=87, createdTime=2019-10-10, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be116e61073, moduleTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be116e61073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652851, encodeId=cc5916528515a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=JCO：高剂量舒尼替尼治疗难治性实体瘤患者的I期临床试验, objectType=article, longId=157056, objectId=382f15e056cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=382f15e056cb, replyNumber=0, likeNumber=55, createdTime=2019-03-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=382f15e056cb, moduleTitle=JCO：高剂量舒尼替尼治疗难治性实体瘤患者的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=382f15e056cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652891, encodeId=d93d165289129, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, objectType=article, longId=165917, objectId=84ae16591e2f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ae16591e2f, replyNumber=0, likeNumber=73, createdTime=2019-11-12, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ae16591e2f, moduleTitle=III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ae16591e2f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652908, encodeId=6f6e165290894, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：IPH4102治疗晚期T细胞淋巴瘤的I期临床试验结果, objectType=article, longId=174329, objectId=68c11e432912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68c11e432912, replyNumber=0, likeNumber=56, createdTime=2019-12-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68c11e432912, moduleTitle=Lancet：IPH4102治疗晚期T细胞淋巴瘤的I期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68c11e432912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652867, encodeId=ee54165286e62, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, objectType=article, longId=160546, objectId=fa9316054665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa9316054665, replyNumber=0, likeNumber=90, createdTime=2019-11-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa9316054665, moduleTitle=III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa9316054665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652887, encodeId=9e66165288e16, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性, objectType=article, longId=164499, objectId=73ff16449919, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73ff16449919, replyNumber=0, likeNumber=65, createdTime=2020-02-11, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73ff16449919, moduleTitle=III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73ff16449919)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652869, encodeId=0c86165286980, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, objectType=article, longId=160563, objectId=3f571605635b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f571605635b, replyNumber=0, likeNumber=82, createdTime=2019-05-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f571605635b, moduleTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f571605635b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652923, encodeId=f39e16529239d, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, objectType=article, longId=177383, objectId=b6d81e73834c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d81e73834c, replyNumber=0, likeNumber=66, createdTime=2020-06-09, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d81e73834c, moduleTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d81e73834c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2019-05-06

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

天境生物宣布完成自主新药TJM2美国I期临床首次人体给药

2019-06-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

"PANDA"登陆悉尼！康柏西普全球多中心III期临床试验启动

2019-02-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Biomed Res Int：牙槽嵴成形术中侧向Ramus皮质骨板同时使用颊脂垫衍生细胞和自体骨：I期临床试验

2020-01-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点

2020-02-17

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册

2020-03-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果

2020-04-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功

2019-12-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

FDA批准新型心血管支持液VBI-1进入II期临床试验

2019-05-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

短肠综合征：双效多肽药物ZP7570正在进行I期临床试验

2020-03-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

II期j临床试验成功而III期临床失败的案例教训

2019-06-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet Oncol：张力教授领衔——中国抗肿瘤药物研发的挑战与改变：肿瘤学I期临床试验年度报告

2019-04-14

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色

2019-10-10

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

JCO：高剂量舒尼替尼治疗难治性实体瘤患者的I期临床试验

2019-03-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床试验证实Fc融合凝血因子延长半衰期，可为血友病患者提供有效的围手术期止血

2019-11-12

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：IPH4102治疗晚期T细胞淋巴瘤的I期临床试验结果

2019-12-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床试验证实Keytruda联用阿西替尼显著降低晚期肾癌的死亡率

2019-11-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性

2020-02-11

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案

2019-05-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率

2020-06-09

科室
- - 订阅+
  - 更多科室
工具
服务